Bart A. Jessen
Impact in
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- Ophthalmology top 5%
Papers in
-
- Drug-Induced Ocular Toxicity 7
- Oncology 7
- Cancer-related Molecular Pathways 3
- Co-authors
- Shuyan Lu (9 shared papers)Yvonne Will (3 shared papers)Sashi Nadanaciva (2 shared papers)Tae Sung (4 shared papers)Wenyue Hu (7 shared papers)William D. Pennie (1 shared paper)David F. Gebhard (1 shared paper)Brad P. Hirakawa (5 shared papers)
- Journals
- Toxicological Sciences (5 papers)Molecular Cancer Therapeutics (3 papers)Journal of Ocular Pharmacology and Therapeutics (3 papers)Toxicologic Pathology (3 papers)Toxicology in Vitro (3 papers)
- Partner nations
- United StatesSwitzerlandCanada
In The Last Decade
Bart A. Jessen
43 papers receiving 1.5k citations
Peers
Comparison fields: 5 of 87
- Oncology 299
- Ophthalmology 80
- Pharmacology 73
- Cell Biology 91
- Immunology 128
Countries citing papers authored by Bart A. Jessen
This map shows the geographic impact of Bart A. Jessen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bart A. Jessen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bart A. Jessen more than expected).
Fields of papers citing papers by Bart A. Jessen
This network shows the impact of papers produced by Bart A. Jessen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bart A. Jessen. The network helps show where Bart A. Jessen may publish in the future.
Co-authors
The 25 scholars most cited alongside Bart A. Jessen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 43 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2014 | 243 | |
| 2 | 2008 | 183 | |
| 3 | 2010 | 178 | |
| 4 | 2015 | 144 | |
| 5 | 2017 | 121 | |
| 6 | 2002 | 66 | |
| 7 | 2013 | 50 | |
| 8 | 2007 | 40 | |
| 9 | 2012 | 36 | |
| 10 | 2003 | 34 | |
| 11 | 2009 | 34 | |
| 12 | 2021 | 31 | |
| 13 | 1995 | 29 | |
| 14 | 2001 | 28 | |
| 15 | 2018 | 28 | |
| 16 | 2006 | 22 | |
| 17 | 2012 | 20 | |
| 18 | 2012 | 20 | |
| 19 | 2004 | 18 | |
| 20 | 2000 | 17 |
About Bart A. Jessen
Bart A. Jessen is a scholar working on Ophthalmology, Oncology, Cell Biology, Small Animals and Immunology, having authored 43 papers that have together received 1.6k indexed citations. Recurring topics across this work include Drug-Induced Ocular Toxicity (7 papers), Immunotoxicology and immune responses (5 papers), Chemotherapy-induced cardiotoxicity and mitigation (4 papers), Skin and Cellular Biology Research (4 papers), Animal testing and alternatives (4 papers), Advanced Breast Cancer Therapies (3 papers), Carcinogens and Genotoxicity Assessment (3 papers) and Cancer-related Molecular Pathways (3 papers). The work is most often cited by research in Oncology (299 citations), Ophthalmology (80 citations), Pharmacology (73 citations), Cell Biology (91 citations) and Immunology (128 citations). Bart A. Jessen has collaborated with scholars based in United States, Switzerland and Canada. Frequent co-authors include Shuyan Lu, Yvonne Will, Sashi Nadanaciva, Tae Sung, Wenyue Hu, William D. Pennie, David F. Gebhard, Brad P. Hirakawa, Joseph D. Jamieson and Robert H. Rice. Their work appears in journals such as Toxicological Sciences, Molecular Cancer Therapeutics, Journal of Ocular Pharmacology and Therapeutics, Toxicologic Pathology and Toxicology in Vitro.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.